Neratinib manufacturers and suppliers in india

Neratinib

Properties

Melting point:: 185-187°C

Boiling point:: 757.0±60.0 °C(Predicted)

Density: 1.33

storage temp.: Refrigerator

solubility: Chloroform (Slightly), DMSO (Slightly, Heated, Sonicated), Methanol (Slightly, Heated)

form: Off-white solid.

pka: 12.37±0.43(Predicted)

color: Pale Yellow to Yellow

Safety Information

Symbol(GHS): GHS05

Signal word: Danger

Hazard statements: H314-H290

Precautionary statements: P501-P234-P264-P280-P390-P303+P361+P353-P301+P330+P331-P363-P304+P340+P310-P305+P351+P338+P310-P406-P405

HS Code: 29334900

Use

Neratinib developed by US Wyeth company is an irreversible epidermal growth factor receptor(EGFR) inhibitor. It is a multiple target point of small molecule tyrosine kinase inhibitors to HER 2 and HER1 after Lapatinib, and is an irreversible ErbB receptor tyrosine kinase inhibitor. Neratinib could selectively inhibit HER-1 and HER-2 of EGFR family(IC50 was 92 nmol/L and 59 nmol/L, respectively). Clinical research showed that Neratinib exerted significant therapeutic effect on non-small cell lung cancer, colon cancer, and breast cancer. The phaseⅡclinical trial indicated that Neratinib showed good efficacy and tolerance to HER-2 positive patients with advanced breast cancer who had been received or not Trastuzumab treatment. The phase Ⅲ breast cancer clinical trial was complete in September 2014. The data indicated that the efficacy of Neratinib was better than Roche's Herceptin in treatment of HER-2 positive early breast cancer. The above information is edited by the Chemicalbook of Liu Yujie.